Articles related to GLYCEMIC CONTROL

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

The FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding a device previously limited to adults and supporting caregiver-supervised home glucose monitoring.

In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.

Among 206,464 mother-child pairs, children of mothers with stably optimal glycemic management after a GDM diagnosis had obesity risk at age 10 nearly identical to children unexposed to GDM. Children of mothers with suboptimal trajectories had a 62% higher risk.

Pediatric patients who started automated insulin delivery within 6 months of type 1 diabetes diagnosis had a median HbA1c of 7.1% at 24 months versus 9.8% in non-users in a US multicenter retrospective cohort.

“A lot of people think that sugar feeds cancer. But what if I told you that cutting sugar too aggressively could also have negative, unexpected effects?” — Eric K. Singhi, MD